Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as ...
Two global partnerships surfaced across metabolic disease and oncology this week, as Novo and AstraZeneca each moved to expand their pipelines through deals with clinical-stage in ...
Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. Merck entered into an ...
Incyte received a Rare Pediatric Disease Priority Review Voucher tied to zilurgisertib’s FOP approval, while Mirum plans U.S.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...
Pharmaceutical Executive spoke with Michael Abrams, managing partner at global healthcare consultancy Numerof & Associates ...
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient ...
FDA authorization is underpinned by four global Phase III QWINT studies showing non-inferior A1C lowering versus glargine ...
The FDA's movement to encourage real-world data use through downstream acceptance is, in effect, a call to action for ...
As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to ...
Chief executives from nine of Europe's largest drugmakers are calling on the European Union (EU) and its member states to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results